A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation

Transplant International

Volumn 26, Issue 6, 2013, Pages 631-639

  Nakasone, Hideki ^a,n   Kanda, Junya ^a   Yano, Shingo ^b   Atsuta, Yoshiko ^c   Ago, Hiroatsu ^d   Fukuda, Takahiro ^e   Kakihana, Kazuhiko ^f   Adachi, Tatsuya ^g   Yujiri, Toshiaki ^h   Taniguchi, Shuichi ⁱ   Taguchi, Jun ^j   Morishima, Yasuo ^k   Nagamura, Tokiko ^l   Sakamaki, Hisashi ^f   Mori, Takehiko ^m   Murata, Makoto ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g Meitetsu Hospital   (Japan)

^h YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ TORANOMON HOSPITAL   (Japan)

^j NAGASAKI UNIVERSITY   (Japan)

^k AICHI CANCER CENTER HOSPITAL   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

^m KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

ABO mismatch; allogeneic hematopoietic stem cell transplantation; bronchiolitis obliterans syndrome; cord blood; graft versus host disease

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD COMPATIBILITY; BRONCHIOLITIS OBLITERANS; CASE CONTROL STUDY; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; BRONCHIOLITIS OBLITERANS; BUSULFAN; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84877960821     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12093     Document Type: Article

References (39)

1. Afessa B, Litzow MR, Tefferi A,. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425.
2. Yoshihara S, Yanik G, Cooke KR, Mineishi S,. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 749.
3. Chien JW, Duncan S, Williams KM, Pavletic SZ,. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: S106.
4. Soubani AO, Uberti JP,. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J 2007; 29: 1007.
5. Williams KM, Chien JW, Gladwin MT, Pavletic SZ,. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306.
6. Bacigalupo A, Chien J, Barisione G, Pavletic S,. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. Semin Hematol 2012; 49: 15.
7. Filipovich AH, Weisdorf D, Pavletic S, et al,. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945.
8. Epler GR, Colby TV,. The spectrum of bronchiolitis obliterans. Chest 1983; 83: 161.
9. Santo Tomas LH, Loberiza Jr FR, Klein JP, et al,. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153.
10. Ringden O, Remberger M, Ruutu T, et al,. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196.
11. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ,. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657.
12. Yoshihara S, Tateishi U, Ando T, et al,. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005; 35: 1195.
13. Nakaseko C, Ozawa S, Sakaida E, et al,. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol 2011; 93: 375.
14. Atsuta Y, Suzuki R, Yoshimi A, et al,. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007; 86: 269.
15. Giralt S, Ballen K, Rizzo D, et al,. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367.
16. Przepiorka D, Weisdorf D, Martin P, et al,. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825.
17. Shulman HM, Sullivan KM, Weiden PL, et al,. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204.
18. Montgomery RA, Cozzi E, West LJ, Warren DS,. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol 2011; 23: 224.
19. Rydberg L,. ABO-incompatibility in solid organ transplantation. Transfus Med 2001; 11: 325.
20. Novick RJ, Schafers HJ, Stitt L, et al,. Recurrence of obliterative bronchiolitis and determinants of outcome in 139 pulmonary retransplant recipients. J Thorac Cardiovasc Surg 1995; 110: 1402; discussion 13-4.
21. Cai J,. Intestine and multivisceral transplantation in the United States: a report of 20-year national registry data (1990-2009). Clin Transpl 2009; 83.
22. Kocher AA, Schlechta B, Ehrlich M, et al,. Effect of ABO blood type matching in cardiac transplant recipients. Transplant Proc 2001; 33: 2752.
23. Sjogren J, Ljungdahl-Waller F, Senneby E, Ekmehag B, Koul B, Nilsson J,. Heart transplantation with ABO-identical versus ABO-compatible cardiac grafts: influence on long-term survival. Scand Cardiovasc J 2010; 44: 373.
24. Yu NC, Haug MT 3rd, Khan SU, et al,. Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? J Heart Lung Transplant 1999; 18: 764.
25. Sano Y, Date H, Nagahiro I, Aoe M, Shimizu N,. Relationship between anti-ABO antibody production and hemolytic anemia after minor ABO-mismatched living-donor lobar lung transplantation. Transplant Proc 2005; 37: 1371.
26. Shortt J, Westall GP, Roxby D, et al,. A 'dangerous' group O donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies. Am J Transplant 2008; 8: 711.
27. Kimura F, Sato K, Kobayashi S, et al,. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica 2008; 93: 1686.
28. Worel N, Greinix HT, Keil F, et al,. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002; 42: 1293.
29. Yazer MH, Triulzi DJ,. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 2007; 14: 664.
30. Worel N, Greinix HT, Schneider B, et al,. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000; 40: 543.
31. Rabitsch W, Knobl P, Prinz E, et al,. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Bone Marrow Transplant 2003; 32: 1015.
32. Griffith LM, McCoy JP Jr, Bolan CD, et al,. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128: 668.
33. Nilsson TK, Sondell KM, Norberg BO, Back O,. Plasma levels of endothelial-derived haemostatic factors in autoimmune thrombocytopenia and haemolytic anaemia. J Intern Med 1990; 228: 249.
34. Rother RP, Bell L, Hillmen P, Gladwin MT,. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293: 1653.
35. Tanabe M, Kawachi S, Obara H, et al,. Current progress in ABO-incompatible liver transplantation. Eur J Clin Invest 2010; 40: 943.
36. Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A,. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant 2004; 33: 509.
37. Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM,. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008; 3: 60.
38. Fischer A, du Bois R,. Interstitial lung disease in connective tissue disorders. Lancet 2012; 380: 689.
39. Zhang H, Chen J, Que W,. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients. Biol Blood Marrow Transplant 2012; 18: 1164.